Drug – bio-affecting and body treating compositions – Identification or warning feature – Taste or smell or chemical irritation to the eye – nose – or...
Patent
1988-09-12
1990-07-03
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Identification or warning feature
Taste or smell or chemical irritation to the eye, nose, or...
514476, A61K 4700
Patent
active
049389491
ABSTRACT:
Various types of biological treatments, including antineoplastic treatments with antineoplastic drugs, can result in damage to the blood-forming function of the bone marrow. This damage can be reversed, at least to some degree, with an effective amount (preferably an extremely low dose) of a pharmaceutically acceptable dithiocarbamic compound, including a compound of the formula R.sub.1 R.sub.2 NCSSM or R.sub.1 R.sub.2 NCSS--SCSNR.sup.3 R.sup.4, wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are the same or different aliphatic or cycloaliphatic or heterocycloaliphatic groups, unsubstituted or substituted by hydroxyl, or one of R.sup.1 and R.sup.2 and one of R.sup.3 and R.sup.4 can be H, or R.sup.1 and R.sup.2 or R.sup.3 and R.sup.4, taken together with the N atom upon which the pair of R groups is substituted, can be a 5- or 6-member N-heterocyclic ring which is aliphatic or aliphatic interrupted by a ring oxygen or second ring nitrogen, and M is H or one equivalent of a pharmaceutically acceptable cation, in which case the rest of the molecule is negatively charged. The dosage in mammals can range from about 0.001 to 30 mg/kg of body weight. For larger mammals, including humans, a typical dosage unit is less than 10 mg/kg, e.g. <3 mg/kg. The dosage unit can be dissolved in a suitable pharmaceutically acceptable carrier (e.g. an aqueous medium) and is then preferably administered intravenously within 8 hours of the administration of the agent which can cause bone marrow damage. The extremely low dosages particularly preferred in this invention do not cause any significant side effects.
REFERENCES:
patent: 4148885 (1979-04-01), Renoux et al.
patent: 4594238 (1986-06-01), Borch
patent: 4645661 (1987-02-01), Schonbaum
D. L. Bodenner et al, Cancer Res. 46, 2751-2755 (1986).
M. M. Jones et al, Cancer Chemother. Pharmacol. 17, 38-42 (1986).
D. A. Juckett et al, Proc. AACR, Abstracts 25, 322, Abstr. No. 1274 (1984).
Chemical Abstract 105(3): 17989p, Selective Protection Against Cis-Diamminedichloroplatinum (II)-Induced Toxicity in Kidney, Gut, and Bone Marrow by Diethyl-Dithiocarbamate, Bodenner et al.
Borch Richard F.
Schmalbach Therese K.
Henley III Raymond J.
Robinson Douglas W.
University of New York
LandOfFree
Treatment of damaged bone marrow and dosage units therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of damaged bone marrow and dosage units therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of damaged bone marrow and dosage units therefor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1889537